FDA Inspection 1163359 — Lilly Del Caribe, Inc

Lilly Del Caribe, Inc — FEI 2619243

The FDA completed an inspection of Lilly Del Caribe, Inc on Feb 25, 2022 in Carolina, PR. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Feb 25, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Carolina, PR (United States)

Citations

IDCFRDescription
202821 CFR 211.192Extent of discrepancy, failure investigations
360321 CFR 211.160(b)Scientifically sound laboratory controls

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.